[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]
- PMID: 1168122
- DOI: 10.1055/s-0028-1106260
[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]
Abstract
The anti-hypertensive effect of spironolactone and thiabutazide was tested on 47 unselected patients with primary hypertension. They were divided into two groups according to the change in plasma-renin activity in response to furosemide administration: those with and those without response to stimulation, and sub-groups with low, normal or high plasma-renin activity (low renin hypertension; normal renin hypertension; high renin hypertension). During both 4-week treatment periods there was a distinct fall in systolic blood pressure, most marked in the patients without plasma renin stimulation (after spironolactone of about 26.2 mm Hg, after thiabutazide 29 mm Hg), the diastolic pressure fall being only slight in all groups (about 5-10 mm Hg). The plasma-renin activity and plasma-aldosterone concentration increased in all groups, after both spironolactone and thiabutazide three-to fourfold compared with the basal value, even in patients without change in plasma-renin activity after furosemide injections. Serum sodium content decreased after administration of spironolactone, increasing again after subsequent thiabutazide administration. Serum potassium content increased after spironolactone, decreasing after thiabutazide. There was no significant difference between either individual groups or different treatment periods with spironolactone or thiabutazide as far as weight, urine volume or electrolyte excretion in 24-hour urine was concerned.
Similar articles
-
[Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)].Dtsch Med Wochenschr. 1978 Oct 20;103(42):1650-5. doi: 10.1055/s-0028-1129316. Dtsch Med Wochenschr. 1978. PMID: 699788 Clinical Trial. German.
-
[Treatment of benign essential hypertension with an association of spironolactone and thiabutazide: an open multicenter study in general practice (author's transl)].Schweiz Rundsch Med Prax. 1981 Dec 8;70(50):2269-78. Schweiz Rundsch Med Prax. 1981. PMID: 7031639 Clinical Trial. German. No abstract available.
-
[Treatment of essential hypertension with propranolol (author's transl)].Dtsch Med Wochenschr. 1976 Oct 8;101(41):1482-8. doi: 10.1055/s-0028-1104295. Dtsch Med Wochenschr. 1976. PMID: 183943 Clinical Trial. German.
-
Spécificités du traitement médicamenteux antihypertenseur chez la femme.Presse Med. 2019 Nov;48(11 Pt 1):1261-1264. doi: 10.1016/j.lpm.2019.07.028. Epub 2019 Nov 14. Presse Med. 2019. PMID: 31735525 Review. French.
-
Studies on the New Zealand strain of genetically hypertensive rats.Clin Sci Mol Med Suppl. 1973 Aug;45 Suppl 1:15s-21. doi: 10.1042/cs045015s. Clin Sci Mol Med Suppl. 1973. PMID: 4593562 Review. No abstract available.
Cited by
-
Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism.Klin Wochenschr. 1978 Apr 1;56(7):341-9. doi: 10.1007/BF01477394. Klin Wochenschr. 1978. PMID: 642407 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources